Business
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million
PARIS, November 13, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/867f304ef3204069bec6756f111723de"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SYQYgWxiz2Lbq5wuI4YZsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/867f304ef3204069bec6756f111723de","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, November 13, 2025--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 1,999,998.1515 fundraising (the "Fundraising").","length":363,"tagName":"p"},{"type":"text","content":"The Fundraising resulted in the issuance of:","length":44,"tagName":"p"},{"type":"text","content":"(i) 15,980,844 ordinary shares (actions ordinaires) of the Company (the "Offered Shares"), which were admitted to trading on Euronext Paris on November 12, 2025 (ISIN FR0013183985/SIGHT);","length":197,"tagName":"p"},{"type":"text","content":"(ii) 3,492,063 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 3,492,063 additional ordinary shares; and","length":155,"tagName":"p"},{"type":"text","content":"(iii) 19,472,907 warrants (the "Offered Investor Warrants") giving the right to subscribe to 19,472,907 additional ordinary shares.","length":141,"tagName":"p"},{"type":"text","content":"The Offered Investor Warrants were admitted to trading on the Euronext Growth market in Paris on November 12, 2025 (ISIN FR0014010IB4/SIGBS). The Offered Pre-Funded Warrants will not be admitted to trading on any venue.","length":219,"tagName":"p"},{"type":"text","content":"Risk factors","length":12,"tagName":"p"},{"type":"text","content":"The Company draws the attention of the p...